Client Ramius Offers to Acquire Therapeutic Drugmaker for $154M
Olshan's client Ramius LLC offered to buy drugmaker Cypress Bioscience Inc. for approximately $154 million and asked the board to abstain from approving any further acquisitions. Ramius currently holds a 9.9% stake in Cypress. The Wall Street Journal (subscription required) and Forbes, among other media, reported on the story.
Steve Wolosky, Andrew M. Freedman, Amanda S. Lamson, and Michael D. DeDonato with litigation assistance from Thomas J. Fleming comprise the Olshan team representing Ramius.